Consortium backs series-B for Leon-Nanodrugs

Harriet Matthews
17 April 2020

Tweet
Facebook
LinkedIn
Google plus
Send to

A consortium of investors including TVM Capital, CD-Venture, Albany Private Equity, Eckenstein-Geigy-Stiftung, LOF Leon Partnership, Evotec and BayBG has backed a series-B for nanotechnology developer Leon-Nanodrugs.

Following the round and under a separate agreement, the company will establish a partnership with Evotec to develop its nanomedicine technology further.

Evotec CFO Enno Spillner and BayBG investment manager Peter Graf will join the company's supervisory board, which currently includes TVM Capital Life Science managing partner Hubert Birner, Gerhard Ries of LifeCare Partners, James Gale of Signet Healthcare Partners and Frank Mathias of Rentschler Biotechnologie.

BayBG generally invests €100,000-7m in Bavaria-based companies and has joined the series-B as a new investor.

Previous funding
In July 2015, Leon-Nanodrugs completed a €8.5m funding round led by TVM Capital. Also participating were Signet Healthcare Partners, LifeCare Partners, CD-Venture and Albany Private Equity.

Company
Leon-Nanodrugs was founded in 2011. The company has a patented MJR (microjet reactor) nanotechology platform through which it reformulates approved or promising small molecule and protein drug candidates. Its technology has applications in the pharmaceutical and biotechnology industries in the development of active pharmaceutical ingredients.

The company is based in Munich and has 16 employees, according to LinkedIn.

People
Leon Nanotechnology – Andrea Cusack (CEO); Christian Nafe (CFO).
TVM Capital – Hubert Birner (managing partner).